MCM
DNLI icon

MAI Capital Management’s Denali Therapeutics DNLI Stock Holding History

MAI Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Buy
49,160
+2,570
+6% +$52.8K ﹤0.01% 869
2026
Q1 		$895K Buy
46,590
+64
+0.1% +$1.27K 0.01% 814
2025
Q4 		$768K Hold
46,526
– – ﹤0.01% 828
2025
Q3 		$676K Hold
46,526
– – ﹤0.01% 826
2025
Q2 		$651K Hold
46,526
– – ﹤0.01% 771
2025
Q1 		$633K Hold
46,526
– – ﹤0.01% 748
2024
Q4 		$948K Buy
+46,526
New +$1.19M 0.01% 651

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAI Capital Management's DNLI Position: Q2 2026 in Review

MAI Capital Management increased its Denali Therapeutics (DNLI) stake by 5.5% in Q2 2026, buying an estimated $52.8K and bringing the position to 49,160 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #869.

MAI Capital Management first reported a position in DNLI in Q4 2024 and has held it in 7 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • MAI Capital Management held 49,160 shares of Denali Therapeutics worth $1.26M as of Q2 2026.
  • MAI Capital Management bought 2,570 Denali Therapeutics shares in Q2 2026, an estimated $52.8K.
  • Denali Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #869 holding.
  • MAI Capital Management first reported a position in Denali Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.